Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesPhase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Journal of Clinical Oncology, 09/01/09
Escudier B et al. – Sunitinib 37.5 mg, administered on a continuous once–daily dosing regimen, has a manageable safety profile as second–line mRCC therapy, providing flexible dosing, which can be explored in combination studies.
Related Articles
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09
Relevance Score: 89%
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate
Investigational New Drugs, 10/08/09
Relevance Score: 88%
Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib
Clinical Cancer Research, 11/16/09
Relevance Score: 87%
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature
Medical Oncology, 10/23/09
Relevance Score: 87%
Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array
British Journal of Cancer, 11/13/09
Relevance Score: 84%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
Annals of Oncology, 11/24/09
Effect of Chronic Sildenafil Treatment on Penile Endothelial Function: A Randomized, Double-Blind, Placebo Controlled Study
The Journal of Urology, 11/24/09
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
The Journal of Urology, 11/23/09
Today in Kidney...keeping you current
Receive free subspecialty "5-minute updates" via email
Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy
BJU International, 11/25/09
Status quo of percutaneous nephrolithotomy in children
Urological Research - Urolithiasis, 11/25/09
Transplant Nephrectomy Associates with Improved Survival in Patients with Failed Renal Allograft
Journal of the American Society of Nephrology, 11/25/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment
International Journal of Medical Sciences , 11/25/09
Prospective studies of dietary alpha-linolenic acid intake and prostate cancer risk: a meta-analysis
Cancer Causes and Control, 11/25/09
Dysfunction of natural killer cells in patients with transitional cell carcinoma
Cancer Letters, 11/25/09
Article Search
Sponsor